TEIJIN LTD/ JP3544000007 /
2024-09-05 8:10:49 AM | Chg. +0.1500 | Volume | Bid7:08:23 AM | Ask7:08:23 AM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
8.2000EUR | +1.86% | 0 Turnover: 0.0000 |
8.4000Bid Size: 600 | 8.5500Ask Size: 600 | 1.62 bill.EUR | - | - |
GlobeNewswire
05-13
Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparath...
GlobeNewswire
05-09
Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with...
GlobeNewswire
01-31
Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for ...
GlobeNewswire
2023-11-29
Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan
Newsfile Corp
2022-11-21
The "Electrification" of the World: Battery Safety and Efficiency Demands Grow Amidst Lofty Global E...
GlobeNewswire
2020-09-09
Radius Health Announces Scientific Presentations on abaloparatide at ASBMR 2020 Annual Meeting